Fiona Lewis-McDougall

Fiona Lewis-McDougall

Auto-generated profile, based on publicly available information

Fiona Lewis-McDougall

Centre for Microvascular Research, Faculty of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2019 in Aging Cell
Verified
Journal Article
Open access
PDF file
FLFiona C. Lewis‐McDougall
Fiona C. Lewis‐McDougall
PRPrashant J. Ruchaya
Prashant J. Ruchaya
EDEva Domenjo‐Vila
Eva Domenjo‐Vila
TTTze Shin Teoh
Tze Shin Teoh
LPLarissa Prata
Larissa Prata
GEGeorgina M Ellison-Hughes
Georgina M Ellison-Hughes
Aging leads to increased cellular senescence and is associated with decreased potency of tissue‐specific stem/progenitor cells. Here, we have done an extensive analysis of cardiac progenitor cells (CPCs) isolated from human subjects with cardiovascular disease, aged 32–86 years. In aged subjects (>70 years old), over half of CPCs are senescent (p16INK4A, SA‐β‐gal, DNA damage γH2AX, telomere length, senescence‐associated secretory phenotype [SASP]), unable to replicate, differentiate, regenerate or restore cardiac function following transplantation into the infarcted heart. SASP factors secreted by senescent CPCs renders otherwise healthy CPCs to senescence. Elimination of senescent CPCs using senolytics abrogates the SASP and its debilitative effect in vitro. Global elimination of senescent cells in aged mice (INK‐ATTAC or wild‐type mice treated with D + Q senolytics) in vivo activates resident CPCs and increased the number of small Ki67‐, EdU‐positive cardiomyocytes. Therapeutic approaches that eliminate senescent cells may alleviate cardiac deterioration with aging and restore the regenerative capacity of the heart.

11 August 2017 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
CVCarla Vicinanza
Carla Vicinanza
IAIolanda Aquila
Iolanda Aquila
MSMariangela Scalise
Mariangela Scalise
FCFrancesca Cristiano
Francesca Cristiano
FMFabiola Marino
Fabiola Marino
DTDaniele Torella
Daniele Torella
Multipotent adult resident cardiac stem cells (CSCs) were first identified by the expression of c-kit, the stem cell factor receptor. However, in the adult myocardium c-kit alone cannot distinguish CSCs from other c-kit-expressing (c-kitpos) cells. The adult heart indeed contains a heterogeneous mixture of c-kitpos cells, mainly composed of mast and endothelial/progenitor cells. This heterogeneity of cardiac c-kitpos cells has generated confusion and controversy about the existence and role of CSCs in the adult heart. Here, to unravel CSC identity within the heterogeneous c-kit-expressing cardiac cell population, c-kitpos cardiac cells were separated through CD45-positive or -negative sorting followed by c-kitpos sorting. The blood/endothelial lineage-committed (Lineagepos) CD45posc-kitpos cardiac cells were compared to CD45neg(Lineageneg/Linneg) c-kitpos cardiac cells for stemness and myogenic properties in vitro and in vivo. The majority (~90%) of the resident c-kitpos cardiac cells are blood/endothelial lineage-committed CD45posCD31posc-kitpos cells. In contrast, the LinnegCD45negc-kitpos cardiac cell cohort, which represents ⩽10% of the total c-kitpos cells, contain all the cardiac cells with the properties of adult multipotent CSCs. These characteristics are absent from the c-kitneg and the blood/endothelial lineage-committed c-kitpos cardiac cells. Single Linnegc-kitpos cell-derived clones, which represent only 1–2% of total c-kitpos myocardial cells, when stimulated with TGF-β/Wnt molecules, acquire full transcriptome and protein expression, sarcomere organisation, spontaneous contraction and electrophysiological properties of differentiated cardiomyocytes (CMs). Genetically tagged cloned progeny of one Linnegc-kitpos cell when injected into the infarcted myocardium, results in significant regeneration of new CMs, arterioles and capillaries, derived from the injected cells. The CSC’s myogenic regenerative capacity is dependent on commitment to the CM lineage through activation of the SMAD2 pathway. Such regeneration was not apparent when blood/endothelial lineage-committed c-kitpos cardiac cells were injected. Thus, among the cardiac c-kitpos cell cohort only a very small fraction has the phenotype and the differentiation/regenerative potential characteristics of true multipotent CSCs.

19 June 2014 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
ASAndrew John Smith
Andrew John Smith
FLFiona C Lewis
Fiona C Lewis
IAIolanda Aquila
Iolanda Aquila
CWCheryl D Waring
Cheryl D Waring
ANAurora Nocera
Aurora Nocera
GEGeorgina M Ellison-Hughes
Georgina M Ellison-Hughes

24 March 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
DTDaniele Torella
Daniele Torella
GEGeorgina M Ellison-Hughes
Georgina M Ellison-Hughes
MTMichele Torella
Michele Torella
CVCarla Vicinanza
Carla Vicinanza
IAIolanda Aquila
Iolanda Aquila
FSFerdinando Carlo Sasso
Ferdinando Carlo Sasso
Background: Diabetes mellitus ( DM ) has multifactorial detrimental effects on myocardial tissue. Recently, carbonic anhydrases ( CAs ) have been shown to play a major role in diabetic microangiopathy but their role in the diabetic cardiomyopathy is still unknown. Methods and Results: We obtained left ventricular samples from patients with DM type 2 (DM‐T2) and nondiabetic ( NDM ) patients with postinfarct heart failure who were undergoing surgical coronary revascularization. Myocardial levels of CA ‐I and CA‐ II were 6‐ and 11‐fold higher, respectively, in DM ‐T2 versus NDM patients. Elevated CA ‐I expression was mainly localized in the cardiac interstitium and endothelial cells. CA ‐I induced by high glucose levels hampers endothelial cell permeability and determines endothelial cell apoptosis in vitro. Accordingly, capillary density was significantly lower in the DM ‐T2 myocardial samples (mean± SE =2152±146 versus 4545±211/mm 2 ). On the other hand, CA‐II was mainly upregulated in cardiomyocytes. The latter was associated with sodium‐hydrogen exchanger‐1 hyperphosphorylation, exaggerated myocyte hypertrophy (cross‐sectional area 565±34 versus 412±27 μm 2 ), and apoptotic death (830±54 versus 470±34 per 10 6 myocytes) in DM ‐T2 versus NDM patients. CA‐II is activated by high glucose levels and directly induces cardiomyocyte hypertrophy and death in vitro, which are prevented by sodium‐hydrogen exchanger‐1 inhibition. CA‐II was shown to be a direct target for repression by micro RNA ‐23b, which was downregulated in myocardial samples from DM ‐T2 patients. MicroRNA‐23b is regulated by p38 mitogen‐activated protein kinase, and it modulates high‐glucose CA‐II–dependent effects on cardiomyocyte survival in vitro. Conclusions: Myocardial CA activation is significantly elevated in human diabetic ischemic cardiomyopathy. These data may open new avenues for targeted treatment of diabetic heart failure.

1 August 2019 in Basic Research in Cardiology
Verified
Journal Article
Open access
PDF file
MPMihai-Nicolae Podaru
Mihai-Nicolae Podaru
LFLaura Fields
Laura Fields
SKSatoshi Kainuma
Satoshi Kainuma
YIYuki Ichihara
Yuki Ichihara
MHMohsin Hussain
Mohsin Hussain
KSKen Suzuki
Ken Suzuki
Reparative macrophages play an important role in cardiac repair post-myocardial infarction (MI). Bone marrow mononuclear cells (BM-MNCs) have been investigated as a donor for cell therapy but with limited clinical success. These cells, however, may be utilized as a source for reparative macrophages. This translational study aimed to establish a robust in vitro protocol to produce functional reparative macrophages from BM-MNCs and to establish pre-clinical evidence of the efficacy of reparative macrophage transplantation for the treatment of MI. Mouse BM-MNCs were treated with M-CSF plus IL-4, IL-10, TGF-β1 or combinations of these in vitro. The concomitant administration of M-CSF and IL-4 produced the highest rate and largest number of CD11b+F4/80+CD206+ reparative macrophages. Expression and secretion of tissue repair-related factors including IGF-1, TGF-β1, VEGF and IL1-ra were remarkably enhanced in reparative macrophages compared to BM-MNCs. These cells were transplanted in a mouse MI model, resulting in evident improvement in cardiac function recovery, compared to BM-MNC transplantation. Histological studies showed that reparative macrophage transplantation enhanced myocardial tissue repair including augmented microvascular formation, reduced cardiomyocyte hypertrophy and attenuated interstitial fibrosis. Moreover, survival of reparative macrophages in the heart post-transplantation was increased compared to BM-MNCs. Reparative macrophage transplantation also increased host-derived reparative macrophages in part through TGF-β secretion. In conclusion, concomitant M-CSF + IL-4 treatment effectively produced reparative macrophages from BM-MNCs in vitro. Transplantation of produced reparative macrophage achieved a superior therapeutic efficacy, compared to BM-MNC transplantation, through the enhanced quantity and quality of donor cell engraftment. Further development of this advanced cell-based therapy is warranted.

1 July 2019 in Biomaterials
Verified
Journal Article
Open access
KKKazuya Kobayashi
Kazuya Kobayashi
YIYuki Ichihara
Yuki Ichihara
NSNobuhiko Sato
Nobuhiko Sato
NUNobuyoshi Umeda
Nobuyoshi Umeda
LFLaura Fields
Laura Fields
KSKen Suzuki
Ken Suzuki
Mesenchymal stromal/stem cell (MSC)-based therapy is a promising approach for the treatment of heart failure. However, current MSC-delivery methods result in poor donor cell engraftment, limiting the therapeutic efficacy. To address this issue, we introduce here a novel technique, epicardial placement of bi-layered, adhesive dressings incorporating MSCs (MSC-dressing), which can be easily fabricated from a fibrin sealant film and MSC suspension at the site of treatment. The inner layer of the MSC dressing, an MSC-fibrin complex, promptly and firmly adheres to the heart surface without sutures or extra glues. We revealed that fibrin improves the potential of integrated MSCs through amplifying their tissue-repair abilities and activating the Akt/PI3K self-protection pathway. Outer collagen-sheets protect the MSC-fibrin complex from abrasion by surrounding tissues and also facilitates easy handling. As such, the MSC-dressing technique not only improves initial retention and subsequent maintenance of donor MSCs but also augment MSC's reparative functions. As a result, this technique results in enhanced cardiac function recovery with improved myocardial tissue repair in a rat ischemic cardiomyopathy model, compared to the current method. Dose-dependent therapeutic effects by this therapy is also exhibited. This user-friendly, highly-effective bioengineering technique will contribute to future success of MSC-based therapy.